转移性乳腺癌患者中抗体药物偶联物治疗相关不良事件 (TRAE) 的发生率：系统评价和荟萃分析。
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis.
发表日期：2024 Oct 10
作者：
Silvia Belloni, Paola Tiberio, Rita De Sanctis, Arianna Magon, Armando Santoro, Alberto Zambelli, Rosario Caruso, Cristina Arrigoni
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
抗体药物偶联物 (ADC) 正在彻底改变转移性乳腺癌治疗，与化疗相比，其预后更好，安全性更高。然而，与治疗相关的不良事件（TRAE）已被广泛记录。我们检索了五个数据库中截至 2023 年 12 月发表的文章，并对 23 项临床试验进行了荟萃分析，以估计与当前批准的 ADC 相关的 TRAE 患病率。最常见 TRAE 的发生率为 12% 至 33%，具体取决于 ADC 类型和研究设计。胃肠道疾病在曲妥珠单抗 Deruxtecan 治疗期间非常常见，一般疾病在曲妥珠单抗 Emtansine 治疗期间极其常见，血液系统疾病和胃肠道疾病在 Sacituzumab Govitecan 治疗期间最常见。本研究根据研究设计对每种治疗的 ADC 相关 TRAE 进行了估计。尽管每种 ADC 都有特定的毒性，但胃肠道症状在所有治疗中都非常普遍。这项研究为开发个性化风险分层护理途径奠定了基础。版权所有 © 2024 Elsevier B.V. 保留所有权利。
Antibody-drug conjugates (ADCs) are revolutionizing metastatic breast cancer treatment, resulting in a better prognosis and a higher safety profile than chemotherapy. Nevertheless, treatment-related adverse events (TRAE) have been extensively documented. We searched five databases for articles published up to December 2023 and conducted a meta-analysis on 23 clinical trials to estimate TRAE prevalence related to currently approved ADCs. The prevalence of the most common TRAEs ranged from 12 % to 33 %, depending on the ADC type and study design. Gastrointestinal disorders were highly prevalent during Trastuzumab Deruxtecan, general disorders were extremely common during Trastuzumab Emtansine, and blood system disorders and gastrointestinal disorders were the most prevalent during Sacituzumab Govitecan. This study provides an estimate of ADC-related TRAEs for each treatment based on study design. Despite each ADC having specific toxicities, gastrointestinal symptoms were highly prevalent in all treatments. This study lays the groundwork for developing personalized risk-stratified care pathways.Copyright © 2024 Elsevier B.V. All rights reserved.